Blog / Archives
Life Science Stocks In Third Day of Sell-Off
Todays' Movers : CSII and IMGN Life Science and Drug stocks hit their third day of selling about 4% off July highs but 6% higher than June lows. The bellwether ETF IBB remains 6% above intermediate...
Review of Life Science Funds and ETF’s up 15% YTD
Edited Version Published in Investor Uprising June 2011 :Updated here JY 16, 2011 Biotechnology Has Outperformed the S&P Over Five Years Medical science has always been an important area for...
Sector Watch: Energy on Fire,Techs Strong,Healthcare a Bit Weak
Large cap drug and biotech stocks sold off as buyers favor technology. Within the NASDAQ-100 up 1% led by GOOG, BIDU and SIRI. Alexion (ALXN $52.19) bucked the weakness in biotech up 1.74% but GILD,...
Macro Rules Market: QE3 Buzz is Off
Life Science Sector Outperforms NASDAQ-100: Movers are ROSGD, VICL Biotechnology stocks sold off about 0.65% overall as industry news and fundamentals were eclipsed by MACRO issues. Concerns loom...
Rayno Life Sciences Portfolio Update: MITI, QGEN, SGEN
Life Science Stocks are Stable in a Choppy Market; Macro Is Dominating The NASDAQ market stabilized today (but down 0.54%) after a two day sell-off that brought the qqq down to $57.79 from the...
NYT Article Raises Issues with Genomics Tests with Cancer Patients
A front page article in the New York Times today by Gina Kolata, "How Bright Promise in Cancer Testing Fell Apart", chronicles a patient case study at Duke University about gene based tests for lung...
Rayno Life Science Portfolio Tools and Dx-Big Winners YTD: CRA,CSII,EXAS,GPRO
Diagnostics is Still a Hot Ticket The Rayno Life Science Tools and Diagnostics Portfolio is up 12% YTD with big winners Celera up 31%, recently acquired by Quest Diagnostics (DGX), Cardiovascular...
Rayno Life Science Portfolio Tools and Dx: Immucor (BLUD) Up 30% on Buyout
TPG Capital Offers $1.97B for diagnostic Company focused in blood donor screening. TPG Capital is a private equity firm with $48B in assets. Immucor was added to the Rayno Life Science Portfolio in...
Rayno Life Science Portfolio 2011 H1 Update-Biopharm Big Winners:BIIB, CBST, REGN, SGEN
2011 A Huge Year for Life Science Investing As of mid-year the Rayno Life Science Biopharmaceutical Portfolio was up over 20% beating most ETF's and Life Science mutual funds. Our two recommended...
Trends From BIO International Conference: Biotech Sector Performance YTD,MTD
The 2011 Bio Meeting was well attended surpassing last year's number around 15,000. International participation continues to grow with 37% of attendees outside of the U.S. Virtually every country...